Corpus overview


MeSH Disease

HGNC Genes

plexin A2 (1)

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 5 records in total 5
    records per page

    Demand for Self-Managed Online Telemedicine Abortion in Eight European Countries During the COVID-19 MESHD COVID-19 MESHD Pandemic: A Regression Discontinuity Analysis

    Authors: Abigail R.A. Aiken; Jennifer E Starling; Rebecca Gomperts; James G Scott; Catherine Aiken

    doi:10.1101/2020.09.15.20195222 Date: 2020-09-18 Source: medRxiv

    Objectives: In most European countries, patients seeking medication abortion during the COVID-19 MESHD COVID-19 MESHD pandemic are still expected to attend healthcare settings in person despite lockdown measures and infection risk. We assessed whether demand for self-managed medication abortion provided by a fully remote online telemedicine service increased following the emergence of COVID-19 MESHD. Design: We used regression discontinuity to compare the number of requests to online telemedicine service Women on Web in eight European countries before and after they implemented lockdown measures to slow COVID-19 MESHD transmission. We examined the number deaths due to COVID-19 MESHD, the degree of government-provided economic support, the severity of lockdown travel restrictions, and the medication abortion service provision model in countries with and without significant changes in requests. Setting: Eight European countries served by Women on Web. Participants: 3,915 people who made requests for self-managed abortion to Women on Web between January 1st, 2019 and June 1st, 2020. Main Outcome Measures: Percent change in requests to Women on Web before and after the emergence of COVID-19 MESHD and associated lockdown measures. Results: Five countries showed significant increases in requests, ranging from 28% in Northern Ireland (p=0.001) to 139% in Portugal (p<0.001). Two countries showed no significant change in requests, and one country, Great Britain, showed an 88% decrease in requests (p<0.001). Countries with significant increases in requests were either countries where abortion services are mainly provided in hospitals or where no abortion services are available and international travel was prohibited during lockdown. By contrast, Great Britain authorized teleconsultation for medication abortion MESHD and provision of medications by mail during the pandemic. Conclusion: These marked changes in requests for self-managed medication abortion during COVID-19 MESHD demonstrate demand for fully remote models of abortion MESHD care and an urgent need for policymakers to expand access to medication abortion by telemedicine.

    Fixed single-cell RNA sequencing for understanding virus infection and host response

    Authors: Hoang Van Phan; Michiel van Gent; Nir Drayman; Anindita Basu; Michaela Gack; Savas Tay; Patricio O. Craig; Leandro A. Cossio; Liliana Dain; Fernanda Elias; Natalia B. Fernandez; Javier Gasulla; Natalia Gorojovsky; Gustavo E. Gudesblat; Maria G. Herrera; Lorena I. Ibañez; Tommy Idrovo; Matias Iglesias Rando; Laura Kamenetzky; Alejandro D Nadra; Diego G. Noseda; Carlos H. Pavan; Maria F. Pavan; Maria F. Pignataro; Ernesto Roman; Lucas A.M Ruberto; Natalia Rubinstein; Javier Santos; Francisco Velazquez; Alicia M. Zelada; Catherine M.K. Ho; Chelsea L Kennard; Daniel Knott; Stephanie Leung; Vanessa Lucas; Adam Mabbutt; Alexandra L Morrison; Didier Ngabo; Jemma Paterson; Elizabeth J Penn; Steve Pullan; Irene Taylor; Tom Tipton; Stephen Thomas; Julia A Tree; Carrie Turner; Nadina Wand; Nathan R Wiblin; Sue Charlton; Bassam Hallis; Geoffrey Pearson; Emma L Rayner; Andrew G Nicholson; Simon G Funnell; Mike J Dennis; Fergus V Gleeson; Sally Sharpe; Miles W Carroll

    doi:10.1101/2020.09.17.302232 Date: 2020-09-17 Source: bioRxiv

    Single-cell RNA sequencing studies requiring intracellular protein staining, rare-cell sorting, or pathogen inactivation are severely limited because current high-throughput methods are incompatible with paraformaldehyde treatment, a very common and simple tissue/cell fixation and preservation technique. Here we present FD-seq, a high-throughput method for droplet-based RNA sequencing of paraformaldehyde-fixed, stained and sorted single-cells. We used FD-seq to address two important questions in virology. First, by analyzing a rare population of cells supporting lytic reactivation of the human tumor MESHD virus KSHV, we identified TMEM119 as a host factor that mediates reactivation. Second, we studied the transcriptome of lung cells infected with the 2 coronavirus OC43, which causes the common cold and also serves as a safer model pathogen for SARS-CoV-2. We found that pro-inflammatory pathways are primarily upregulated in abortively-infected MESHD or uninfected bystander cells, which are exposed to the virus but fail to express high level of viral genes. FD-seq is suitable for characterizing rare cell populations of interest, for studying high-containment biological samples after inactivation, and for integrating intracellular phenotypic with transcriptomic information.

    COVID-19 MESHD and first trimester spontaneous abortion: a case-control study of 225 pregnant patients

    Authors: Stefano Cosma; Andrea Carosso; Jessica Cusato; Fulvio Borella; Marco Carosso; Marialuisa Bovetti; Claudia Filippini; Antonio D'Avolio; Valeria Ghisetti; Giovanni Di Perri; Chiara Benedetto

    doi:10.1101/2020.06.19.20135749 Date: 2020-06-20 Source: medRxiv

    Background Evidence for the impact of COVID-19 MESHD during the second and the third trimester of pregnancy is limited to a relatively small series, while data on the first trimester are scant. With this study we evaluated COVID-19 MESHD infection as a risk factor for spontaneous abortion MESHD in first trimester of pregnancy. Methods Between February 22 and May 21, 2020, we conducted a case-control study at S. Anna hospital, Torino, among first trimester pregnant women, paired for last menstruation. The cumulative incidence of COVID-19 MESHD was compared between women with spontaneous abortion MESHD (case group, n=100) and those with ongoing pregnancy (control group, n=125). Current or past infection was determined by detection of SARS-CoV-2 from nasopharingeal swab and SARS-CoV-2 IgG/IgM antibodies in blood sample. Patient demographics, COVID-19 MESHD-related symptoms, and the main risk factors for abortion MESHD were collected. Findings Twenty-three (10.2%) of the 225 women tested positive for COVID-19 MESHD infection. There was no difference in the cumulative incidence of COVID-19 MESHD between the cases (11/100, 11%) and the controls (12/125, 9.6%) (p=0.73). Logistic regression analysis confirmed that COVID-19 MESHD was not an independent predictor of abortion (1.28 confidence interval 0.53-3.08). Interpretation COVID-19 MESHD infection during the first trimester of pregnancy does not appear to predispose to abortion; its cumulative incidence did not differ from that of women with ongoing pregnancy.

    Impact of COVID-19 MESHD infection on maternal and neonatal outcomes: a review of 287 pregnancies

    Authors: Fatemeh Azarkish; Roksana Janghorban

    doi:10.1101/2020.05.09.20096842 Date: 2020-05-15 Source: medRxiv

    Pregnant women are vulnerable group in viral outbreaks especially in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The aim of this review was to identify maternal and neonatal outcomes in available articles on pregnancies affected by COVID-19 MESHD. The articles that had assessed outcomes of pregnancy and perinatal of women with COVID-19 MESHD between Oct HGNC 2019 and Apr 30, 2020 without language limitation were considered. All kinds of studies such as case report, case series, retrospective cohort, case control were included. We searched databases, selected relevant studies and extracted data regarding maternal and neonatal outcomes from each article. Data of 287 pregnant women with COVID-19 MESHD of 6 countries were assessed from 28 articles between December 8, 2019 and April 6, 2020. Most pregnant women reported in their third trimester, 102 (35.5%) cases were symptomatic at the time of admission. Common onset symptoms, abnormal laboratory findings, and chest computed tomography pattern were fever MESHD (51.5%), lymphocytopenia MESHD (67.9%), and multiple ground-glass opacities (78.5%) respectively. 93% of all deliveries were done through cesarean section. No maternal mortality and 3 % ICU admission were reported. Vertical transmission was not reported but its possibility was suggested in three neonates. One neonatal death MESHD, one stillbirth, and one abortion MESHD were reported. All newborns were not breastfed. This review showed fewer adverse maternal and neonatal outcomes in pregnant women with COVID-19 MESHD in comparison with previous coronavirus outbreak infection MESHD in pregnancy. Limited data are available regarding possibility of virus transmission in utero, during vaginal childbirth and breastfeeding. Effect of COVID-19 MESHD on first and second trimester and ongoing pregnancy outcomes in infected MESHD mothers is still questionable.

    Effects of Coronavirus Disease 2019 MESHD ( COVID-19 MESHD) on Maternal, Perinatal and Neonatal Outcomes: a Systematic Review of 266 Pregnancies

    Authors: Juan Juan; Maria M Gil; Zhihui Rong; Yuanzhen Zhang; Huixia Yang; Liona Chiu Yee Poon

    doi:10.1101/2020.05.02.20088484 Date: 2020-05-06 Source: medRxiv

    Objective: To perform a systematic review of available published literature on pregnancies affected by COVID-19 MESHD to evaluate the effects of COVID-19 MESHD on maternal, perinatal and neonatal outcomes. Methods: We performed a systematic review to evaluate the effects of COVID-19 MESHD on pregnancy, perinatal and neonatal outcomes. We conducted a comprehensive literature search using PubMed, EMBASE, Cochrane library, China National Knowledge Infrastructure Database and Wan Fang Data until April 20, 2020 (studies were identified through PubMed alert after April 20, 2020). For the research strategy, combinations of the following keywords and MeSH terms were used: SARS-CoV-2, COVID-19 MESHD, coronavirus disease 2019 MESHD, pregnancy, gestation, maternal, mothers, vertical transmission, maternal-fetal transmission, intrauterine transmission, neonates, infant, delivery. Eligibility criteria included laboratory-confirmed and/or clinically diagnosed COVID-19 MESHD, patient was pregnant on admission, availability of clinical characteristics, including maternal, perinatal or neonatal outcomes. Exclusion criteria were unpublished reports, unspecified date and location of the study or suspicion of duplicate reporting, and unreported maternal or perinatal outcomes. No language restrictions were applied. Results: We identified several case-reports and case-series but only 19 studies, including a total of 266 pregnant women with COVID-19 MESHD, met eligibility criteria and were finally included in the review. In the combined data from seven case-series, the maternal age ranged from 20 to 41 years and the gestational age on admission ranged from 5 to 41 weeks. The most common symptoms at presentation were fever MESHD, cough, dyspnea MESHD/ shortness of breath MESHD and fatigue MESHD. The rate of severe pneumonia MESHD was relatively low, with the majority of the cases requiring intensive care unit admission. Almost all cases from the case-series had positive computer tomography chest findings. There were six and 22 cases that had nucleic-acid testing in vaginal mucus and breast milk MESHD samples, respectively, which were negative for SARS-CoV-2. Only a few cases had spontaneous miscarriage or abortion MESHD. 177 cases had delivered, of which the majority by Cesarean section. The gestational age at delivery ranged from 28 to 41 weeks. Apgar scores at 1 and 5 minutes ranged from 7 to 10 and 8 to 10, respectively. A few neonates had birthweight less than 2500 grams and over one-third of cases were transferred to neonatal intensive care unit. There was one case each of neonatal asphyxia MESHD and neonatal death MESHD. There were 113 neonates that had nucleic-acid testing in throat swab, which was negative for SARS-CoV-2. From the case-reports, two maternal deaths among pregnant women with COVID-19 MESHD were reported. Conclusions: The clinical characteristics of pregnant women with COVID-19 MESHD are similar to those of nonpregnant adults with COVID-19 MESHD. Currently, there is no evidence that pregnant women with COVID-19 MESHD are more prone to develop severe pneumonia MESHD, in comparison to nonpregnant patients. The subject of vertical transmission of SARS-CoV-2 remains controversial and more data is needed to investigate this possibility. Most importantly, in order to collect meaningful pregnancy and perinatal outcome data, we urge researchers and investigators to reference previously published cases in their publications and to record such reporting when the data of a case is being entered into a registry or several registries.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.